Abstract

Fungal diseases are a serious health burden worldwide with drug resistance compromising efficacy of the limited arsenal of antifungals available. New drugs with novel mechanisms of action are desperately needed to overcome current challenges. The screening of the Aspergillus fumigatus genome identified 35 phosphatases, four of which were previously reported as essential for viability. In addition, we validated another three essential phosphatases. Phosphatases control critical events in fungi from cell wall integrity to cell cycle, thus they are attractive targets for drug development. We used VSpipe v1.0, a virtual screening pipeline, to evaluate the druggability of the seven essential phosphatases and identify starting points for drug discovery. Targeted virtual screening and evaluation of the ligand efficiency plots created by VSpipe, enabled us to define the most favourable chemical space for drug development and suggested different modes of inhibition for each phosphatase. Interestingly, the identified ligand binding sites match with functional sites (active site and protein interaction sites) reported for other yeast and human homologues. Thus, the VSpipe virtual screening approach identified both druggable and functional sites in these essential phosphatases for further experimental validation and antifungal drug development.

Highlights

  • Fungal diseases are an ever-increasing burden to health services worldwide with approximately 1.2 billion people suffering from some form of fungal infection [1]

  • A total of 32 protein phosphatases have previously been identified in the genome of the human pathogenic fungus A. fumigatus using an early version of a phosphatase ontology based on domain architecture scanning [14], and by bioinformatics analyses [10]

  • The third protein belongs to the serine threonine phosphoprotein phosphatase (PPP) family (AfuA_5g08620, PpefA)

Read more

Summary

Introduction

Fungal diseases are an ever-increasing burden to health services worldwide with approximately 1.2 billion people suffering from some form of fungal infection [1]. The majority of these cases are the result of superficial, albeit problematic, fungal infections of the skin or mucosa, yet between 1.5 and 2 million deaths are caused each year by systemic infections [2]. Four classes of drugs are currently recommended for the treatment of invasive diseases, with the azole class recommended for primary therapeutic purposes in many instances. Resistance to azoles is emerging rapidly in some key pathogens, Aspergillus fumigatus. New targets and therapeutic classes are urgently needed to overcome the current challenges in treating fungal diseases

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call